Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures
Sign Up to like & getrecommendations! Published in 2017 at "Osteoporosis International"
DOI: 10.1007/s00198-017-4108-y
Abstract: To the editor, Cases have recently been published about reboundassociated vertebral fractures (RAVFs) after discontinuation of denosumab in patients with postmenopausal osteoporosis [1]. Denosumab therapy lasted between 6 and 42 months, and clinical spontaneous fractures… read more here.
Keywords: switching denosumab; denosumab; discontinuation denosumab; vertebral fractures ... See more keywords